A virtual biotech can outsource nearly all of its execution, but it cannot outsource strategy, decisions, accountability or the work of integrating its vendors into one program. Virtual companies succeed when a small core team owns those things deliberately, with clear decision rights, a thoughtful vendor architecture and governance that keeps everyone pointed at the same milestone.
What must a virtual biotech keep in-house?
The development strategy and clinical plan.
Key decisions: protocol design, vendor selection, go and no-go calls.
Integration across CRO, manufacturing, regulatory and specialty vendors.
Regulatory accountability and safety oversight.
Ownership of data and documents.
Budget control and forecasting.
The program's memory: why decisions were made and what was learned.
What does a lean core team look like?
Often a chief executive, a chief medical or scientific officer, a development or clinical operations leader, a CMC lead and finance, supported by regulatory and quality expertise that may be consultant-based. Some roles may be fractional. What matters is that every critical function has a named owner and that owners know where their authority ends.
How should a virtual biotech design its vendor architecture?
Decide whether a full-service CRO or a set of specialist vendors fits the program better, and who will own the integration in either case. Keep the number of vendors manageable for the team you have. Align contracts so responsibilities, data flows and timelines connect rather than overlap or leave gaps.
Where should the program's memory live?
With the sponsor. Keep a decision log, a sponsor-controlled document repository and clear ownership of the trial master file. When consultants rotate or a CRO changes, knowledge should not leave with them. Virtual companies are especially vulnerable to losing institutional memory, because so much of it sits outside their walls.
What are the common failure modes?
Too many vendors for the team to coordinate. Heavy dependence on individual consultants with no continuity plan. Nobody responsible for integration, so problems surface at the seams. Decisions drifting to vendors by default because the sponsor didn't make them. And costs creeping as scope expands through many small changes.
Can a virtual model be a strength?
Absolutely. It offers capital efficiency, access to specialized expertise and flexibility to scale up or down as the program evolves. The difference between a virtual biotech that thrives and one that struggles is rarely the vendors. It is whether the core team behaves like the owner of the program rather than a customer of its suppliers.
When does a virtual biotech need more internal capability?
When it moves to a larger or multi-study program, when vendor coordination starts consuming the core team, or when decisions are repeatedly delayed for lack of internal expertise. Interim or fractional leadership can bridge that gap while the company decides what to build permanently.
Building the core leadership a virtual model depends on? Explore ABRA's Executive Leadership support.
